Sellas Life Sciences Rides a Sector Wave as Its Own Leukemia Trial Hits the Home Stretch

Sellas stock rises 17% on Merck-Moderna vaccine data, but the real catalyst is the Phase-3 REGAL trial nearing its 80-event threshold.

The biotech tape has a way of rewarding patience with serendipity. For Sellas Life Sciences, the past week delivered both: a sympathy rally sparked by rivals' success, layered on top of an approaching catalyst that has been months in the making. The stock climbed 17 percent on Friday, propelled by positive Phase-3 data from Merck and Moderna's personalized cancer vaccine program — a readout that, while unrelated to Sellas' own pipeline, has investors treating the entire immuno-oncology complex with fresh enthusiasm.

The Merck-Moderna results, reported by CNBC on August 19, showed a meaningful extension in relapse-free survival among melanoma patients, with the risk of cancer spread materially reduced. Moderna shares jumped more than 12 percent on Wednesday and roughly 177 percent across the week. But the spillover effect tells a deeper story: Sellas is now trading as a proxy for the broader class of immune-based cancer therapies, a dynamic that Maxim Group explicitly acknowledged on August 21 when it framed the Moderna data as constructive for Sellas' upcoming readout.

The Real Catalyst Sits Closer to Home

Behind the sector-driven noise, however, lies the actual substance of the Sellas thesis. The company's Phase-3 REGAL trial, evaluating Galinpepimut-S (GPS) in acute myeloid leukemia, is now just two events shy of the 80 pre-specified survival events required to lock the database and unblind the study. The slow crawl toward that threshold has been read by some market observers as a quietly encouraging sign — if patients on GPS were faring worse than those on standard therapy, the events would likely have accumulated faster.

The stock has already responded to the narrowing countdown. Since the company reported second-quarter results roughly two weeks ago, shares have advanced 30.5 percent. Friday's session saw the equity touch 12.60 euros, a 12 percent gain on the day, according to the secondary report — though the primary source cites a 17 percent move, reflecting intraday volatility around the same catalyst.

Analysts are firming up their conviction as the binary moment approaches. Alliance Global Partners lifted its price target from $25 to $35, while Maxim Group reiterated its $30 target, viewing competitor progress as validation of the technology class as a whole.

A Pipeline Beyond the Flagship

REGAL may be the headline act, but Sellas is quietly building a supporting cast. The Phase-2 study of SLS009 in newly diagnosed AML patients has enrolled 28 of 80 planned participants as of August 11, with management noting recruitment running ahead of industry norms. Topline data from that trial are expected in the fourth quarter of 2026. Early preclinical signals also point to potential activity in advanced pancreatic cancer resistant to RAS inhibitors — an early-stage avenue that broadens the pipeline's optionality, even if clinical validation remains distant.

The balance sheet supports the wait. Sellas held roughly $138.3 million in cash at the end of June, sufficient to fund operations and clinical programs well beyond the near term. The second quarter did bring a net loss of $9.6 million, with operating expenses climbing to $10.6 million as the company scales manufacturing capacity in anticipation of a potential Biologics License Application submission to the FDA.

The Valuation Question

The chart, at this point, is almost as dramatic as the science. Sellas shares have gained 367 percent year-to-date and 771 percent over twelve months, according to the primary source. The stock sits 143 percent above its 200-day moving average — a stretch that invites questions about how much optimism is already priced in. With a relative strength index of 68.3 and 30-day annualized volatility of 106 percent, the equity is moving in territory that most technicians would describe as overheated.

Yet the stock remains 13 percent below its 52-week high of 15.25 euros, reached in late June. That gap suggests the recent rally has been about reclaiming lost ground rather than breaking new ceiling — a nuance that tempers the froth narrative somewhat.

Institutional conviction has been building alongside the retail enthusiasm. The institutional ownership stake has doubled to 36.34 percent, per Seeking Alpha data from August 2 — a signal that professional investors are adding exposure ahead of the event rather than waiting on the sidelines.

The setup is straightforward: a near-term binary catalyst, a well-funded balance sheet, sector tailwinds, and growing institutional sponsorship. The flip side is equally clear — with so much riding on a single readout, a miss would likely unwind the gains as quickly as they accumulated. For now, the market is betting that the final two events tell a favorable story.